SQ-standardised grass tablet sublingual immunotherapy: persistent clinical benefit and progressive immunological changes during three years treatment.
Durham
Stephen R
SR
Imperial College London, National Heart & Lung Institute, UK-London SW3 6LY.
D000286:Administration, Sublingual; D000485:Allergens / Q000008:administration & dosage* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003888:Desensitization, Immunologic / Q000379:methods*; D006801:Humans; D010936:Plant Extracts / Q000008:administration & dosage* / Q000592:standards / Q000627:therapeutic use; D006109:Poaceae / Q000276:immunology; D011058:Pollen / Q000276:immunology; D012015:Reference Standards; D006255:Rhinitis, Allergic, Seasonal / Q000276:immunology / Q000628:therapy*; D013997:Time Factors; D016896:Treatment Outcome
D000485:Allergens; C551013:Grazax; D010936:Plant Extracts